Diffuse large B cell lymphoma without immunoglobulin light chain restriction by flow cytometry

Acta Haematologica

Volumn 121, Issue 4, 2009, Pages 196-201

  Tomita, Naoto ^a   Takeuchi, Kengo ^b   Hyo, Rie ^c   Hashimoto, Chizuko ^d   Takemura, Sachiya ^e   Taguchi, Jun ^f   Fujita, Hiroyuki ^a   Fujisawa, Shin ^c   Ogawa, Koji ^g   Motomura, Shigeki ^d   Ishigatsubo, Yoshiaki ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b CANCER INSTITUTE   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e Fujisawa City Hospital   (Japan)

^f SHIZUOKA RED CROSS HOSPITAL   (Japan)

^g Yokosuka City Hospital   (Japan)

Author keywords

CD10; CD5; Diffuse large B cell lymphoma; Flow cytometry; Light chain restriction

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CHROMOSOME ANALYSIS; CLINICAL FEATURE; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TRANSPORT;

ADULT; AGED; ANTIGENS, CD5; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CLONE CELLS; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; GENES, BCL-2; GENES, MYC; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 66049137338     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000220332     Document Type: Article

References (14)

1. Taylor CR: Results of multiparameter studies of B-cell lymphomas. Am J Clin Pathol 1979; 72: 687-698. (Pubitemid 10188366)
2. Kaleem Z, Zehnbauer BA, White G, Zutter MM: Lack of expression of surface immunoglobulin light chains in B-cell non-Hodgkin lymphomas. Am J Clin Pathol 2000; 113: 399-405. (Pubitemid 30217388)
3. Jaffe ES, Harris NL, Stein H, Vardiman JW: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon, IARC Press, 2001.
4. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
5. Tomita N, Kodama F, Motomura S, Koharazawa H, Fujita H, Harano H, Kanamori H, Ishigatsubo Y: Prognostic factors in diffuse large B-cell lymphoma treated by risk-adopted therapy. Intern Med 2006; 45: 247-252.
6. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
7. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y: Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 2002; 95: 576-580. (Pubitemid 34810183)
8. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
9. Li S, Eshleman JR, Borowitz MJ: Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B-cell lymphoma. Am J Clin Pathol 2002; 118: 229-234. (Pubitemid 44698448)
10. Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, Yoshino T, Suzumiya J, Murase T, Miura I, Ohshima K, Nishikori M, Tamaru J, Taniwaki M, Hirano M, Morishima Y, Ueda R, Shiku H, Nakamura S: De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 2008; 93: 1195-1202.
11. Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, Takahashi S, Komatsu H, Ikeda K, Yamaguchi M, Suzuki R, Tanimoto M, Hatake K: CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008; 19: 1921-1926.
12. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282. (Pubitemid 38029949)
13. Fabiani B, Delmer A, Lepage E, Guettier C, Petrella T, Brière J, Penny AM, Copin MC, Diebold J, Reyes F, Gaulard P, Molina TJ, Groupe d'Etudes des Lymphomes de l'Adulte: CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Arch 2004; 445: 545-551.
14. Biasoli I, Morais JC, Scheliga A, Milito CB, Romano S, Land M, Pulcheri W, Spector N: CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse largecell lymphoma with very good or very poor prognoses. Histopathology 2005; 46: 328-333. (Pubitemid 40343180)